References
- Claus R, Almstedt M, Luebbert M. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents. Semin Oncol 2005; 32: 511–520
- The Economist. Re-establishing Control. 14 Oct 2006, pp. 86.
- Richard L, Piekarz R F, Turner M, Wright J, Allen S, Kirschbaum M H, et al. Phase II trial of romidepsin, FK228, in cutaneous and peripheral T-cell lymphoma: clinical activity and molecular markers. Blood 2006; 108: 2469
- Duan H, Heckman C A, Boxer L M. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 2005; 25: 1608–1619
- Bereshchenko O R, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002; 32: 606–613
- Kretzner L, Scuto A, Juhasz A, Jove R, Yen Y, Forman S J, et al. Combination of the histone deacetylase inhibitor vorinostat and dasatinib increases apoptosis in Bcr-abl+ cells and reverses changes associated with CML progression. Blood 2006; 108: 2165
- Phiel C J, Zhang F, Huang E Y, Guenther M G, Lazar M A, Klein P S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734–36741
- Garcia-Manero G, Kantarjian H M, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108: 3271–3279
- Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
- Cheson B D, Pfistner B, Juweid M E, Gascoyne R D, Specht L, Horning S J. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586
- Bolden J E, Peart M J, Johnstone R W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769–784